ArticleNature communications2026
Late-stage N-Me selective alkenylation and alkynylation of drugs and unactivated tertiary amines using photoredox catalysis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Late-stage functionalization (LSF) of marketed drugs facilitates novel chemical space around drug leads. Considering alkyl tertiary amines are present in a large number of life-saving drugs, the development of a LSF strategy to introduce functionalizable groups provides a toolbox for future drug discovery. The introduction of vinyl and alkyne groups into a marketed drug also offers numerous advantages and potential applications, including augmented structural diversity, bio-orthogonal labeling, click chemistry, pharmacological modulation, and drug conjugation strategies. Herein, we report a synthetic strategy for N-methyl selective alkenylation and alkynylation of aliphatic tertiary amines using organophotoredox catalysis and their application to the late-stage functionalization of marketed drugs. Molecular modeling followed by bioactivity studies of novel imipramine alkenylated and alkynylated analogues shows improved efficiency compared to imipramine in reducing the depressive state, justifying the importance of N-methyl selective alkenylation and alkynylation. A thorough investigation of the reaction mechanism has been conducted to understand the regioselective formation of the N-Me selective product. DFT calculations combined with experimental evidence indicate that the regioselective outcome is controlled by the radical addition step not the radical formation step, which mostly remains unknown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.